- Home
- BSX
as 05-30-2025 11:32am EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 138.4B | IPO Year: | 1992 |
| Target Price: | $111.64 | AVG Volume (30 days): | 6.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.37 | EPS Growth: | 15.23 |
| 52 Week Low/High: | $71.88 - $107.17 | Next Earning Date: | 07-23-2025 |
| Revenue: | $17,554,000,000 | Revenue Growth: | 19.36% |
| Revenue Growth (this year): | 17.56% | Revenue Growth (next year): | 10.75% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | May 21 '25 | Sell | $106.42 | 4,826 | $513,582.92 | 31,367 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | May 2 '25 | Sell | $104.54 | 4,572 | $477,956.88 | 18,705 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | May 1 '25 | Sell | $102.52 | 164,443 | $16,851,973.70 | 1,535,706 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Apr 21 '25 | Sell | $95.09 | 4,826 | $458,904.34 | 31,367 | |
| Mahoney Michael F | BSX | Chairman, President & CEO | Apr 1 '25 | Sell | $100.01 | 164,442 | $16,445,071.54 | 1,535,706 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Mar 21 '25 | Sell | $100.85 | 4,826 | $486,702.10 | 31,367 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Mar 3 '25 | Sell | $104.80 | 7,631 | $800,896.51 | 432 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 hours ago
We Like These Underlying Return On Capital Trends At Boston Scientific (NYSE:BSX)
StockStory
12 hours ago
3 Market-Beating Stocks with Competitive Advantages
Zacks
18 hours ago
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Argus Research
a day ago
The Argus Sustainable Growth Theme Model Portfolio
Investor's Business Daily
a day ago
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
MT Newswires
2 days ago
Sector Update: Health Care Stocks Softer Wednesday Afternoon
MT Newswires
2 days ago
Sector Update: Health Care
Zacks
2 days ago
PAHC or BSX: Which Is the Better Value Stock Right Now?
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.